全文获取类型
收费全文 | 3526篇 |
免费 | 329篇 |
国内免费 | 77篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 7篇 |
妇产科学 | 5篇 |
基础医学 | 61篇 |
口腔科学 | 6篇 |
临床医学 | 66篇 |
内科学 | 66篇 |
皮肤病学 | 17篇 |
神经病学 | 11篇 |
特种医学 | 11篇 |
外科学 | 29篇 |
综合类 | 336篇 |
预防医学 | 433篇 |
眼科学 | 8篇 |
药学 | 2738篇 |
2篇 | |
中国医学 | 114篇 |
肿瘤学 | 19篇 |
出版年
2024年 | 11篇 |
2023年 | 54篇 |
2022年 | 111篇 |
2021年 | 165篇 |
2020年 | 146篇 |
2019年 | 132篇 |
2018年 | 127篇 |
2017年 | 101篇 |
2016年 | 98篇 |
2015年 | 131篇 |
2014年 | 424篇 |
2013年 | 289篇 |
2012年 | 326篇 |
2011年 | 331篇 |
2010年 | 272篇 |
2009年 | 201篇 |
2008年 | 192篇 |
2007年 | 176篇 |
2006年 | 132篇 |
2005年 | 120篇 |
2004年 | 76篇 |
2003年 | 51篇 |
2002年 | 38篇 |
2001年 | 46篇 |
2000年 | 22篇 |
1999年 | 20篇 |
1998年 | 10篇 |
1997年 | 8篇 |
1996年 | 12篇 |
1995年 | 10篇 |
1994年 | 13篇 |
1993年 | 3篇 |
1992年 | 4篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1988年 | 2篇 |
1985年 | 7篇 |
1984年 | 25篇 |
1983年 | 5篇 |
1982年 | 8篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1979年 | 7篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1975年 | 4篇 |
排序方式: 共有3932条查询结果,搜索用时 31 毫秒
1.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
2.
3.
4.
5.
《中国现代医生》2019,57(4):95-99
目的 探讨临床药师在急性下肢深静脉血栓患者个体化治疗中的作用。 方法 对南京鼓楼医院血管外科2018年8月收治的8例急性下肢深静脉血栓患者的治疗过程进行分析,结合临床药学知识制定导管接触性溶栓及抗凝用药方案,对患者实施全程药学监护。 结果 溶栓治疗期间,患者血浆纤维蛋白原水平呈明显下降趋势,血浆D-二聚体水平呈先升高后降低的趋势,血小板未见明显下降趋势;8例患者在溶栓治疗过程中,2例出现轻微牙龈出血后自行止血,1例出现血尿,停止溶栓治疗后改为口服抗凝药,血尿现象消失。患者预后改善明显,血栓完全溶解,静脉恢复畅通,用药安全得到有效保障。 结论 临床药师在导管接触性溶栓联合抗凝治疗急性下肢深静脉血栓患者的个体化用药监护方面发挥了积极作用。 相似文献
6.
《Health policy (Amsterdam, Netherlands)》2019,123(12):1244-1250
Patient organisations contribute to many areas of pharmaceutical policy. In developing their organisational capacity, many turn to financial support from pharmaceutical companies, which may create conflicts of interests. However, the transparency of the industry’s self-regulatory approach to the disclosure of payments to patient organisations has evaded scrutiny. Using company reports disclosing payments to UK patient organisations in 2012–2016, we evaluate the transparency of reporting using indicators derived from industry’s European patient organisation Code. We found a large proportion of companies did not have any disclosure reports available despite many having made payments, confirmed by comparing with annual financial accounts of patient organisations registered as charities. Where disclosure reports were available, many payments were not adequately described, resulting in large portions of money being disclosed without clarity as to the payment type and purpose. We found companies were clearer regarding whether payments were financial or benefits-in-kind, but transparency was particularly inadequate as to whether it could be determined if payments were indirect or direct and restricted or unrestricted, and almost no companies mentioned the VAT status of payments. Our findings suggest that the industry’s self-regulatory approach to transparency has not been working efficiently. We suggest ways for standardising and increasing the precision of information by pharmaceutical companies and advocate for the introduction of a centralised, and easily accessible national-level payment database. 相似文献
7.
Nuttan K. Tanna 《Pharmacy World & Science》2005,27(1):4-6
The evaluation of healthcare practice and service delivery is fraught with difficulties. Service development and / or delivery occurs within socially dynamic settings which are in a continual state of change. Service development also often involves large elements of improvisation. The action research approach is useful for health service research, as it supports collaboration between researchers and practitioners, and not only allows but makes explicit that the action researcher has both roles within the setting being studied. This paper discusses action research methodology and offers insight into principles that favor its use for service delivery development. This includes consideration of the interactive variables within studies of health care systems and the importance of
evaluating relationships between stakeholders to understand how these factors or variables, which cannot be controlled for, are responsible for successful development of the service. Action research facilitates change and helps bridge the heory--practice gap. With the current dynamic changes within both the pharmacy profession and national health services, researchers may find the action research technique of value
when considering new roles and innovative ways of engaging in collaborative, multi-disciplinary working to improve delivery of patient care.Accepted july 2004 相似文献
8.
Marcel J. Kooy Wouter S. Dessing Esther F. Kroodsma Steven R. J. G. Smits Esther H. Fietje Martine Kruijtbosch Peter A. G. M. De Smet 《Pharmacy World & Science》2007,29(2):81-89
OBJECTIVE: According to a report published by the federation of Dutch patients' associations, patients would like to see a pharmacist, who acts more as a personal adviser. This raised the question, how often Dutch community pharmacists have personal consultations with their patients in daily practice, on which factors this depends, and what kind of topics are discussed during these meetings. SETTING: Community pharmacies in the Netherlands. METHOD: A questionnaire was distributed among 800 randomly selected pharmacies. Questions were restricted to consultations characterized by one-to-one contact, drug therapy related content, and adequate privacy. These consultations were labelled as pharmaceutical consultations in private to distinguish them from other contacts between pharmacists and patients. MAIN OUTCOME MEASURE: Number, content, and character of consultations. RESULTS: 198 (24.8%) community pharmacies responded. The pharmacists provide an average of roughly 1.2 consultations in private per working day. The vast majority of respondents provided face-to-face and telephone consultations (94.4 and 91.9%, respectively), only a minority gave consultations by e-mail (30.8%). These consultations primarily dealt with topics related to medication safety. The mean overall time spent was 290 min per month. A relatively high frequency of personal consultations was significantly associated with the absolute number of full-time equivalent pharmacists in the pharmacy. CONCLUSION: The frequency of pharmaceutical consultations in private is low, but may be improved by reorganisation of the pharmacist's activities. The possibility of personal consultations by e-mail is not yet well-developed. Further research is needed to assess the patient's view of pharmaceutical consultations in private. 相似文献
9.
Almost every national and supranational health policy document accords high importance to the need to listen to and ‘empower’
patients. The relationship between pharmaceutical policy and the lay public is not direct but mediated by several actors,
including health care workers, patient organisations, industry and, most recently, the media. Although the overall aim of
health and pharmaceutical policy is to address the needs of all citizens, there are only a few, well organised groups who
are actually consulted and involved in the policymaking process, often with the support of the industry. The reasons for this
lack of citizen involvement in health and pharmaceutical policymaking are many, for example: there is no consensus about what
public involvement means; there is a predominance of special interest groups with narrow, specific agendas; not all decision
makers welcome lay participation; patients and professionals have different rationalities with regard to their views on medicine.
Because the lay public and medicine users are not one entity, one of the many challenges facing policy makers today is to
identify, incorporate and prioritise the many diverse needs. The authors recommend research which includes studies that look
at: lay attitudes towards pharmaceutical policy; lay experiences of drug therapy and how it affects their daily lives; the
problem of identifying lay representatives; the relationship between industry and the consumers; the effect of the media on
medicine users and on pharmaceutical policy itself. The authors acknowledge that although lay involvement in policy is still
in its infancy, some patient organisations have been successful and there are developments towards increased lay involvement
in pharmaceutical policymaking.
This article is the fourth in a series of articles on this topic that will appear in Pharmacy World & Science during 2005. 相似文献
10.
Oskar Meggeneder 《Zeitschrift fur Gesundheitswissenschaften》2007,15(2):101-107
In a small company, the whole company culture, including the management style, is dominated by the owner. The management culture
in small companies and above all the management style of the owner determine the chances of successfully introducing workplace
health promotion (WHP). For this reason a typology was developed that describes the management personalities who affect the
company culture in small enterprises. This provides a guide to the possible success of WHP in connection with the management
style. Although a summary of the management and corporate culture of small companies in a few categories cannot show the variety
of social reality, it can provide orientation. The typical categories of company social order (a mixture of ownership and
leadership) in small and medium-sized enterprises are given below. Furthermore, there is an assessment of what the chances
of realising workplace health promotion are in each type of company. Small and medium-sized companies (SME) have a number
of organisational characteristics which are just ideal for the introduction and implementation of workplace health promotion.
The work of the employer and employees is often the same. Information in the company is generally comprehensive and easily
available. The lack of information which employees often complain about in large companies is not a problem. There is a good
flow of communication. Small companies have a flat hierarchy that enables participation, the essential requirement for WHP.
There is a close social relationship between the company head and the workforce, although it must be said that this closeness
can be dangerous, particularly if it is misused as complete social control. The readiness to implement Workplace Health Promotion
(WHP) in SME and the degree of success depends largely on the personality of the company manager and the style of leadership.
Considering the importance of a manager’s personality for WHP in SME, modules and instruments to assist company owners and
managers in SME are to be developed. On behalf of and in co-operation with the Austrian Network for Workplace Health Promotion
several modules have been introduced to assist owners and managers of SMEs. 相似文献